The ω-3 carboxylic acid (CA) formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) used in the STRENGTH trial significantly reduced major adverse cardiovascular events (MACE) compared with corn oil in Asian but not in non-Asian patients at high cardiovascular (CV) risk.1 This may help to explain why the EPA/DHA combination did not significantly change the overall CV event rate compared to the corn oil control.2
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
